302 results on '"Kuroi K"'
Search Results
2. Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial
3. Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients
4. A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer
5. Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study)
6. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy
7. 142P Long-term follow-up of neoadjuvant dual anti-HER2 therapy with trastuzumab and lapatinib plus paclitaxel, with or without endocrine therapy for HER2-positive primary breast cancer: Neo-LaTH (JBCRG-16) study
8. Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique
9. Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers: a multi-institution survey
10. Effects of molecular crowding environment on the acquisition of toxic properties of wild-type SOD1
11. Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer
12. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
13. Abstract P3-10-16: Predicting pathological complete response by the combination of microRNAs in patients with HER2-positive primary breast cancer who received neoadjuvant combination therapy of trastuzumab, lapatinib and paclitaxel: Results from JBCRG-16 (NeoLath) study
14. Abstract P2-09-28: New quantitative diagnostic method by fluorescence nanoparticle for HER2 positive breast cancer treated with neoadjuvant lapatinib and trastuzumab: The Neo LaTH study (JBCRG-16TR)
15. HLA-B27 FORMS HEAVY CHAIN HOMODIMERS IN VITRO AND IN VIVO THAT BIND TO CELLULAR RECEPTORS INCLUDING LILR AND KIR FAMILY MEMBERS
16. A global phase III clinical study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients
17. Neoadjuvant therapy with trastuzumab emtansine and pertuzumab in patients with HER2-positive primary breast cancer (A randomized, phase 2 study; JBCRG-20)
18. Abstract P4-21-24: Development of mathematical prediction models to identify disease-free survival events for HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy and trastuzumab
19. Abstract P2-11-07: Duration of fasting before taking lapatinib is associated with skin toxicity in neoadjuvant treatment of HER2 positive breast cancer: A cohort study from JBCRG-16/Neo-LaTH
20. The therapeutic possibility of intrathecal administration of trastuzumab for the carcinomatous meningitis of HER2-positive metastatic breast cancer: the low penetration of trastuzumab into the cerebrospinal fluid via intravenous administration
21. Clinicopathological characteristics and treatment of breast cancer among elderly patients at Tokyo Metropolitan Cancer Center
22. The numbers of Foxp3 positive cells in simultaneous bilateral ER-positive and HER2-negative breast cancer
23. Roles of CD44 and CD24 in predicting response to neoadjuvant chemotherapy
24. Ipsilateral breast recurrence after breast-conserving surgery in young Japanese patients with breast cancer
25. Change in the structure and function of lectin by photodissociation of NO
26. Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer
27. Abstract P1-16-07: Pharmacogenomics-pharmacokinetics study of selective estrogen-receptor modulators with intra-patient dose-escalation for Japanese breast cancer patients
28. 1951 Impact of lapatinib (La) treatment duration and endocrine therapy (ET) addition on the efficacy of primary dual HER2 blockage with La and trastuzumab (T) for HER2+ breast cancer (BC) patients
29. P203 Dual HER2 blockage with lapatinib and trastuzumab for Japanese patients with HER2+ breast cancer
30. 250P - A global phase III clinical study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients
31. 159PD - Neoadjuvant therapy with trastuzumab emtansine and pertuzumab in patients with HER2-positive primary breast cancer (A randomized, phase 2 study; JBCRG-20)
32. 1682 - Clinicopathological characteristics and treatment of breast cancer among elderly patients at Tokyo Metropolitan Cancer Center
33. 264 - Roles of CD44 and CD24 in predicting response to neoadjuvant chemotherapy
34. 230 - Ipsilateral breast recurrence after breast-conserving surgery in young Japanese patients with breast cancer
35. 192 - The numbers of Foxp3 positive cells in simultaneous bilateral ER-positive and HER2-negative breast cancer
36. 189 - The therapeutic possibility of intrathecal administration of trastuzumab for the carcinomatous meningitis of HER2-positive metastatic breast cancer: the low penetration of trastuzumab into the cerebrospinal fluid via intravenous administration
37. P0164 Toxicity profiles of adjuvant docetaxel-cyclophosphamide in Asian compared with caucasian patients with breast cancer
38. Abstract P1-01-03: Interim analysis of the validation study on the clinical usefulness of the ICG fluorescence method for detecting sentinel lymph nodes in early breast cancer compared with the RI method (fICG-BR02)
39. Abstract P6-06-20: Predictive factors for pathologic complete response and disease-free survival after neoadjuvant chemotherapy with trastuzumab: A multicenter retrospective observational study in patients with HER2-positive primary breast cancer (JBCRG-C03 study)
40. Abstract P3-13-08: A phase I study of weekly nab-paclitaxel in combination with S-1 in patients with metastatic breast cancer
41. Abstract P2-10-04: The clinicopathological features of androgen receptor expression in primary HER2-positive breast carcinomas
42. Abstract P6-11-11: Characteristics of long-term survivors after brain metastases in breast cancer patients
43. AOSOP16 DEVELOPMENT OF WEB TOOLS TO PREDICT PATHOLOGICAL RESPONSE TO NEOADJUVANT CHEMOTHERAPY AND AXILLARY LYMPH NODE METASTASIS IN BREAST CANCER PATIENTS
44. Abstract P1-12-01: Evaluation on efficacy and safety of capecitabine plus docetaxel versus docetaxel monotherapy in metastatic breast cancer patients pretreated with anthracycline: Results from a randomized phase III study (JO21095)
45. Abstract P3-06-18: Increase of serum androgen and its metabolites in postmenopausal primary breast cancer patients with disease progression during neo-adjuvant exemestane treatment; JFMC 34–0601 TR
46. Abstract P3-02-06: Survival impact of early detection of recurrence after surgery in early breast cancer patients
47. Abstract P1-14-02: Preoperative docetaxel (T) with or without capecitabine (X) following epirubicin, 5-fluorouracil and cyclophosphamide (FEC) in patients with operable breast cancer (OOTR N003): Results of comparative study and predictive marker analysis
48. Abstract P4-14-07: Impact of preservation of the intercostobrachial nerve during axillary dissection on sensory change and health-related quality of life two years after breast cancer surgery
49. Abstract P6-07-16: Evaluation of circulating tumor cell as a marker of prognosis and efficacy in a randomized phase III study in HER2 negative metastatic breast cancer patients treated with capecitabine and docetaxel: JO21095 study
50. Bolero-2: A Randomized Phase III Study of Everolimus in Combination with Exemestane: Results of the Japanese Subgroup Analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.